Differences

This shows you the differences between two versions of the page.

Link to this comparison view

start [2016/10/16 10:57]
f.demichelis@unitn.it
start [2017/06/06 15:46] (current)
f.demichelis@unitn.it
Line 1: Line 1:
 +{{ :cbio.png?200|[[www.unitn.it/cibio]]}}Our research focuses on the understanding of somatic genomic and epigenetic changes that underpin tumor evolution and progression with emphasis on the characterization of human tumors heterogeneity.  
 +
 +We also study the effect of inherited variants within transcriptionally active regions and chromatin regulators that act at promoter and enhancer elements. Those polymorphic regulatory regions might contribute to the initiation of cancer by modulating the transcriptional activity of multiple gene targets, such as in the case of hormone-regulated tumors.
 +
 +The laboratory integrates computational and experimental work and is characterized by inter-disciplinary/inter-institutional collaborations that allow for a challenging and stimulating atmosphere and state-of-the-art approaches.
 +
 +Follow us on {{:twitter.png?30|[[https://twitter.com/FrancescaBZNY]]}}
 +
 <html>  <html> 
-<span style="color:white;font-size:150%;background-color:#0066FF;font-weight: bold;">+<span style="color:white;font-size:150%;background-color:#00fffa;font-weight: bold;">
 &nbsp;&nbsp;news and notices from our group&nbsp;&nbsp; &nbsp;&nbsp;news and notices from our group&nbsp;&nbsp;
 </span> </span>
Line 6: Line 14:
  
  
-**October 10th 2016**: [[http://www.cell.com/cancer-cell/fulltext/S1535-6108(16)30440-8|N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer]] A study from David Rickman's group with our collaboration published in Cancer Cell.+**June 5th 2017**: **ASCO 2017** Whole exome sequencing of circulating tumor DNA (ctDNA) in patients with neuroendocrine prostate cancer presented at ASCO 2017 was featured in UroToday. Collaboration with Weill Cornell Medicine.([[https://www.urotoday.com/conference-highlights/asco-2017/asco-2017-prostate-cancer/96283-asco-2017-whole-exome-sequencing-of-circulating-tumor-dna-ctdna-in-patients-with-neuroendocrine-prostate-cancer-informs-tumor-heterogeneity.html|article]]).
  
 +----
 +{{ :nature_genetics.jpg?nolink&130}}
 +**October 17th 2016**: [[http://www.nature.com/ng/journal/vaop/ncurrent/full/ng.3692.html|Clonal Evolution of Chemotherapy-resistant Urothelial Carcinoma]] Chemotherapy drives treatment resistance in bladder cancer as revealed by allele-specific CLONET based analysis of bladder cancer tissues. An international team-science collaborative work with Weill Cornell Medicine and the Englander Institute for Precision Medicine ([[http://weill.cornell.edu/news/news/2016/10/chemotherapy-drives-treatment-resistance-in-bladder-cancer.html|press release]]).
  
-**March 10th 2016**: [[http://www.nature.com/nbt/journal/v34/n3/full/nbt.3502.html|Voices of biotech]] **Nature Biotechnology** asks a selection of researchers about the most exciting frontier in their field and the most needed technologies for advancing knowledge and applications.{{ :nature_biotechnology.jpg?nolink&150|}}+----
  
 +**October 10th 2016**: [[http://www.cell.com/cancer-cell/fulltext/S1535-6108(16)30440-8|N-Myc Induces an EZH2-Mediated Transcriptional Program Driving Neuroendocrine Prostate Cancer]] A study from David Rickman's group with our collaboration published in Cancer Cell.
  
-**February 8th 2016**: [[http://dx.doi.org/10.1038/nm.4045|Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer]] study published in Nature Medicine.{{ :nature_medicine.png?nolink&200|}}+---- 
 +{{ :nature_biotechnology.jpg?nolink&150}} 
 +**March 10th 2016**: [[http://www.nature.com/nbt/journal/v34/n3/full/nbt.3502.html|Voices of biotech]] **Nature Biotechnology** asks a selection of researchers about the most exciting frontier in their field and the most needed technologies for advancing knowledge and applications.
  
 +----
 +{{ :nature_medicine.png?nolink&150|}}
 +**February 8th 2016**: [[http://dx.doi.org/10.1038/nm.4045|Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer]] study published in Nature Medicine.
 +
 +----
 **November 5th 2015**: **November 5th 2015**:
 [[http://dx.doi.org/10.1016/j.cell.2015.10.025|The Molecular Taxonomy of Primary Prostate Cancer]] TCGA-PRAD (prostate adenocarcinoma) study published in Cell with our contribution on clonality assessment and some. [[http://dx.doi.org/10.1016/j.cell.2015.10.025|The Molecular Taxonomy of Primary Prostate Cancer]] TCGA-PRAD (prostate adenocarcinoma) study published in Cell with our contribution on clonality assessment and some.
  
-**November 4th 2015**: [[http://dx.doi.org/10.1126/scitranslmed.aac9511|Plasma AR and abiraterone-resistant prostate cancer]] study on the cover of Science Translational Medicine, FOCUS: [[http://dx.doi.org/10.1126/scitranslmed.aad4008|Liquid biopsy: Clues on prostate cancer drug resistance]] {{:stm_cover_nov2015.gif?nolink&50|}}+---- 
 +{{ :stm_cover_nov2015.gif?nolink&50|}} 
 +**November 4th 2015**: [[http://dx.doi.org/10.1126/scitranslmed.aac9511|Plasma AR and abiraterone-resistant prostate cancer]] study on the cover of Science Translational Medicine, FOCUS: [[http://dx.doi.org/10.1126/scitranslmed.aad4008|Liquid biopsy: Clues on prostate cancer drug resistance]]  
 + 
 +----
  
-{{ :erc_logo2.png?150|}}+{{ :erc_logo2.png?nolink&150|}}
 **European Research Council Consolidator grant was awarded to F Demichelis:**\\  **European Research Council Consolidator grant was awarded to F Demichelis:**\\ 
 Synthetic Lethal Phenotype Identification through Cancer Evolution Analysis (SPICE)  Synthetic Lethal Phenotype Identification through Cancer Evolution Analysis (SPICE) 
 [[http://cordis.europa.eu/project/rcn/197873_en.html|ERC-2014-CoG]]; Starting Date: October 1st 2015, 5 yrs. See [[http://demichelislab.unitn.it/doku.php?id=public:positions|Positions]] for open positions (post-docs, PhD students, lab manager, IT technician).  [[http://cordis.europa.eu/project/rcn/197873_en.html|ERC-2014-CoG]]; Starting Date: October 1st 2015, 5 yrs. See [[http://demichelislab.unitn.it/doku.php?id=public:positions|Positions]] for open positions (post-docs, PhD students, lab manager, IT technician). 
 +
 +----
  
  
Line 31: Line 56:
 ---- ----
 ---- ----
- 
- 
-{{ :cbio.png?200|[[www.unitn.it/cibio]]}}Our research focuses on the understanding of somatic genomic and epigenetic changes that underpin tumor evolution and progression with emphasis on the characterization of human tumors heterogeneity.   
- 
-We also study the effect of inherited variants within transcriptionally active regions and chromatin regulators that act at promoter and enhancer elements. Those polymorphic regulatory regions might contribute to the initiation of cancer by modulating the transcriptional activity of multiple gene targets, such as in the case of hormone-regulated tumors. 
- 
-The laboratory integrates computational and experimental work and is characterized by inter-disciplinary/inter-institutional collaborations that allow for a challenging and stimulating atmosphere and state-of-the-art approaches. 
- 
-\\ 
  
 __Current funded projects:__\\ __Current funded projects:__\\